<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738762</url>
  </required_header>
  <id_info>
    <org_study_id>RTPO 976</org_study_id>
    <nct_id>NCT02738762</nct_id>
  </id_info>
  <brief_title>Glutamine Supplementation</brief_title>
  <official_title>Glutamine Supplementation Guided by Plasma Glutamine Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Centre Leeuwarden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Centre Leeuwarden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Earlier studies showed a benefit in survival when glutamine was given intravenously and these&#xD;
      studies lead to recommendations that glutamine should be given to critically ill patients.&#xD;
      The ESPEN guidelines recommend 0,2-0,4 g/kg/d intravenous glutamine added to standard&#xD;
      parenteral nutrition .&#xD;
&#xD;
      Until recently it was not possible to obtain a plasma glutamine level fast enough to consider&#xD;
      the result for clinical decision making. With the availability of a Point of Care (POCT)&#xD;
      measurement of plasma glutamine level a measurement can be performed short after the&#xD;
      collection of blood. This offers the possibility to identify a patient with a low plasma&#xD;
      glutamine level shortly after admission and use repeated measurements for evaluation of the&#xD;
      response to supplementation of glutamine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  At admission (day 0) a plasma glutamine level is measured. The measurement can be&#xD;
           performed from blood taken for the first arterial blood gas analysis. Patients are&#xD;
           eligible for the study when the plasma glutamine level is lower than 420 µmol/l.&#xD;
&#xD;
        -  After informed consent is obtained patients are randomised to receive enteral glutamine&#xD;
           or not ( the control group). Enteral glutamine supplementation is started (day 1) at a&#xD;
           dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams&#xD;
           of L-glutamine ( Glutaperos®, GLNP Life Sciences).&#xD;
&#xD;
        -  Enteral glutamine supplementation will be given for a maximum of 10 days or until the&#xD;
           patient is discharged from the ICU.&#xD;
&#xD;
        -  Plasma glutamine levels will be measured four times a day, at 06.00, 12.00, 18.00 and&#xD;
           00.00 hours, concurrently with the standard arterial blood gas analyses so no extra&#xD;
           blood is taken from the patient.&#xD;
&#xD;
        -  On day 3 at 12.00 hours the dose of glutamine will be increased to 3 times 2 sachets if&#xD;
           plasma glutamine level is still below 420 µmol/l.&#xD;
&#xD;
        -  From day 3 ( 12.00 hrs) until day 10 ( end of study) the dosage of enteral glutamine&#xD;
           will be evaluated daily at 12.00 hours. When the plasma glutamine level is higher than&#xD;
           420 µmol/l the dosage of enteral glutamine will be adjusted according to the schedule&#xD;
           below.&#xD;
&#xD;
        -  In patients who randomized to the control group, the plasma glutamine level will be&#xD;
           measured daily at 12.00 hr concurrently with standard arterial blood gas analysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    materials incomplete&#xD;
  </why_stopped>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amount of enteral glutamine supplementation glutamine level</measure>
    <time_frame>10 days</time_frame>
    <description>amount of enteral glutamine supplementation needed to increase the plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>length of mechanical ventilation</measure>
    <time_frame>10 days</time_frame>
    <description>difference in length of mechanical ventilation between two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospital mortality</measure>
    <time_frame>6 months</time_frame>
    <description>difference in hospital mortality between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Glutamine</condition>
  <condition>Length of Stay</condition>
  <condition>Mechanical Ventilation</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>enteral glutamine supplementation guided by glutamine level Enteral glutamine supplementation is started (day 1) at a dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams of L-glutamine ( Glutaperos®, GLNP Life Sciences). Enteral glutamine supplementation will be given for a maximum of 10 days or until the patient is discharged from the ICU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients receive normal treatment, no glutamine supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>glutamine supplementation</intervention_name>
    <description>glutamine supplementation guided by glutamine levels in plasma</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patients admitted to the ICU with an expected stay of 48 hours or longer&#xD;
&#xD;
          -  glutamine level lower thand 420 mmol/l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age under 18 years&#xD;
&#xD;
          -  readmission to the ICU&#xD;
&#xD;
          -  contra indication for enteral nutrition&#xD;
&#xD;
          -  use of total parental nutrition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matty Koopmans, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>MCL</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Centre Leeuwarden</investigator_affiliation>
    <investigator_full_name>Matty Koopmans</investigator_full_name>
    <investigator_title>MSc</investigator_title>
  </responsible_party>
  <keyword>intensive care</keyword>
  <keyword>glutamine</keyword>
  <keyword>length of stay</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>patient data is anonym</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

